Edesa Biotech Research, Inc.: federal grants and contributions: 3 agreements; $37.1M value; 2 departments; 3 programs.
Assay record ASY-CA-1PMYCDR09H · Cite as: Assay Systems, “Edesa Biotech Research, Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/edesa-biotech-research-inc/
The project will focus on the activities required for Phase 3 clinical trials/regulatory approval for their novel antibody treatment (EB05) targeting acute respiratory distress syndrome (ARDS), the most common cause of death in COVID-19 patients.
Edesa will complete a pre-clinical study, and Phase II trials to evaluate the safety and efficacy of an antibody treatment (EB05) in hospitalized COVID-19 patients.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
All grants from Innovation, Science and Economic Development Canada
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.